Verastem Oncology Announces Design For Confirmatory Trial Of Avutometinib And Defactinib In Recurrent Low-Grade Serous Ovarian Cancer; As Of March 31, 2023, Verastem Oncology Had Cash And Short-Term Investments Of $111.2M
Portfolio Pulse from Happy Mohamed
Verastem Oncology has finalized the design of its Phase 3 trial for the combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer. The trial, RAMP 301, will commence in the second half of 2023. The company also intends to file for accelerated FDA approval based on data from RAMP 201 and the FRAME trial. As of March 31, 2023, Verastem had cash and short-term investments of $111.2M, which increased to approximately $202.7M after a public offering in June 2023.
July 05, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verastem Oncology is advancing its Phase 3 trial for avutometinib and defactinib, which could potentially lead to accelerated FDA approval. The company's financial position is also strong with $202.7M in cash and short-term investments.
The news of Verastem finalizing its Phase 3 trial design and planning to file for accelerated FDA approval is positive for the company. This could potentially lead to a new revenue stream if the drug is approved. Additionally, the company's strong financial position provides it with the necessary resources to continue its operations and invest in further research and development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100